JP2009544734A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544734A5
JP2009544734A5 JP2009521989A JP2009521989A JP2009544734A5 JP 2009544734 A5 JP2009544734 A5 JP 2009544734A5 JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009544734 A5 JP2009544734 A5 JP 2009544734A5
Authority
JP
Japan
Prior art keywords
composition
antagonist
alkyl
substituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/074351 external-priority patent/WO2008014338A2/en
Publication of JP2009544734A publication Critical patent/JP2009544734A/ja
Publication of JP2009544734A5 publication Critical patent/JP2009544734A5/ja
Pending legal-status Critical Current

Links

JP2009521989A 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Pending JP2009544734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
PCT/US2007/074351 WO2008014338A2 (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2009544734A JP2009544734A (ja) 2009-12-17
JP2009544734A5 true JP2009544734A5 (enExample) 2011-03-10

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521989A Pending JP2009544734A (ja) 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト

Country Status (11)

Country Link
US (2) US20080025973A1 (enExample)
EP (1) EP2068856A2 (enExample)
JP (1) JP2009544734A (enExample)
KR (1) KR20090033886A (enExample)
CN (1) CN101505744A (enExample)
AU (1) AU2007279311A1 (enExample)
BR (1) BRPI0714593A2 (enExample)
CA (1) CA2657480A1 (enExample)
MX (1) MX2009000907A (enExample)
WO (1) WO2008014338A2 (enExample)
ZA (1) ZA200900316B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US20110009453A1 (en) * 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
WO2010129553A1 (en) * 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
RU2012105453A (ru) * 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
WO2011038446A1 (en) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Cosmetic foam
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
US20060173046A1 (en) * 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP1935874A4 (en) * 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Similar Documents

Publication Publication Date Title
JP2009544734A5 (enExample)
JP2017514917A5 (enExample)
US20080025973A1 (en) Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
IL308752B2 (en) RNAi factors, compositions and methods of using them for treating transthyretin-related diseases
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2023099171A (ja) 緑内障を治療するためのＷｎｔ５ａの調節
JP2017524012A (ja) 眼科症状を処置するまたは予防するための方法
KR20150013867A (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
EP3747471A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2020505365A (ja) 治療用および神経保護用ペプチド
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
JP7474706B2 (ja) ４－フェニル酪酸を含有する老視の治療または予防剤
CN1450897A (zh) 用于控制iop并治疗青光眼的5ht2兴奋剂
WO2014138018A1 (en) Preservative free bimatoprost and timolol solutions
JP2013535495A (ja) 病的血管新生に関連する病気を予防し、安定させかつ／または阻害するための注射可能な医薬組成物
O'Brien et al. Metastatic Staphylococcus aureus endophthalmitis: a case report.
JP2014521648A (ja) 網膜疾患を治療するための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンゾイミダゾール−５−アミンを含む医薬組成物
EP4574146A1 (en) Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases
JP7641902B2 (ja) 緑内障の新規治療法
RU2023125207A (ru) СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
JPWO2020180865A5 (enExample)
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
JPWO2022232586A5 (enExample)
JP2005533082A5 (enExample)